Back to Resources
Market Highlights
-
AstraZeneca presented new staging guidelines for Imfinzi in NSCLC.
-
BeOne announced a new price for Tevimbra.
-
MSD highlighted a new clinical rating for metastatic NSCLC and reimbursement for new and expanded pembrolizumab indications.
-
Regeneron announced its full ownership of Libtayo.
-
Additional insights are available within this CDP: SnapShot report. Please contact us for further information.
Questions about this SnapShot or other markets?
U.S. MARKETS
Christine Alongi
alongi@dtwresearch.com
GLOBAL MARKETS
Robin Cefalo
cefalo@dtwresearch.com
SOCIAL MEDIA MARKETS
Andrew Carney
carney@dtwresearch.com